April 18, 2016 9:42am
Final Results for the first Six Patients to be released later this quarter
Shares were up 21% premarket and trading falling to +12.27% or +$0.03 to $0.26
Positive interim data from a P2 study, Pathway, assessing its HuCNS-SC human neural stem cells for the treatment of chronic cervical spinal cord injury
The results were presented at the 2016 American Spinal Injury Association annual meeting in Philadelphia.
The Bottom Line: At month six, five of six patients in Cohort I showed an improvement in muscle strength while four of the five demonstrated improved performance on functional tests assessing dexterity and fine motor skills. Also, four of the six showed improvement in the level of cord injury as measured by standards called ISNCSCI. Twelve-month data on the first open-label cohort will be released later this quarter.
STEM has currently enrolled and randomized 19 of the 40 total subjects in the statistically powered, single-blind Cohort II. Enrollment should be completed in September with final results expected in 2017.